Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$1.48
$0.07(4.73%)
At close: 4:00 PM EDT
$1.48
$0.07(4.73%)
Day’s Range― - ―
52-Week Range$1.05 - $8.62
Previous CloseN/A
Volume4.03K
Average Volume (3M)199.18K
Market Cap
$3.11M
Enterprise Value$9.32
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$151.97K
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.70Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.3
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityA low-debt capital structure with positive equity reduces refinancing risk and preserves strategic optionality. For a cash-burning biotech, minimal leverage lengthens runway for clinical programs and commercial investments without immediate debt pressure, supporting durability of execution if financing access is available.
Differentiated Core Product (Arakoda)Arakoda’s unique profile—broad-stage prophylaxis, weekly dosing, and no known resistance—creates a durable commercial advantage in travel and prevention markets. That differentiation supports formulary consideration, prescriber preference, and long-term demand resilience versus commodity antimalarials.
Advancing Babesiosis Trial And Regulatory StrategyA defined interim-analysis plan and enrollment progress provide a clear regulatory path to expand tafenoquine’s label into babesiosis. A successful outcome could materially diversify revenue, enable an NDA submission, and potentially secure a Commissioner’s Priority Review Voucher, accelerating market access.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude creates a structural financing requirement. Without rapid revenue scaling or external capital, the company faces dilution risk or curtailed programs. Cash burn constrains long-term R&D, commercial expansion, and resilience to trial setbacks.
Very Small And Declining Revenue BaseA tiny, shrinking revenue base leaves fixed costs and commercial investments disproportionally large relative to sales. This structural mismatch undermines sustainable margin expansion, forces reliance on external funding or partnerships, and limits ability to self-fund growth or absorb regulatory delays.
Large Net Losses And Negative ReturnsPersistent, sizeable net losses and negative returns indicate the business is not yet generating economic value from operations. Over time, this erodes equity and heightens dependence on capital markets; absent durable margin improvement or new approved indications, sustaining operations will remain challenging.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.05 and its highest was $8.62 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.11M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 14 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.74.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,659,288 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Stock 12 Month Forecast
Average Price Target
$3.70
▲(150.00% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
0.33% Mutual Funds
10.53% Other Institutional Investors
88.06% Public Companies and
Individual Investors